Evidence map›Paper›PMID 29047020›Full record

ReviewInfection2018

Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden.

Abdullah Mahmud-Al-Rafat, Abdul Muktadir, Hasneen Muktadir, Mahbubul Karim, Arpan Maheshwari, Mohammad Mainul Ahasan

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Abdullah Mahmud-Al-RafatResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh.ORCID http://orcid.org/0000-0003-4263-125X
Abdul MuktadirResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh.
Hasneen MuktadirResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh.
Mahbubul KarimResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh.
Arpan MaheshwariResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh.
Mohammad Mainul AhasanResearch & Development Division, Incepta Vaccine Ltd, Zirabo, Savar, Dhaka, 1341, Bangladesh. mainulahasan@inceptavaccine.com.ORCID http://orcid.org/0000-0002-8268-2206
Bangladesh Institute of Development Studies · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRotavirus is the major cause of gastroenteritis in children throughout the world. Every year, a large number of children aged < 5 years die from rotavirus-related diarrhoeal diseases. Though these infections are vaccine-preventable, the vast majority of children in low-income countries suffer from the infection. The situation leads to severe economic loss and constitutes a major public health problem.

methodsWe searched electronic databases including PubMed and Google scholar using the following words: "features of rotavirus," "epidemiology of rotavirus," "rotavirus serotypes," "rotavirus in Bangladesh," "disease burden of rotavirus," "rotavirus vaccine," "low efficacy of rotavirus vaccine," "inactivated rotavirus vaccine". Publications until July 2017 have been considered for this work. RESULTS AND

conclusionCurrently, two live attenuated vaccines are available throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available vaccines, satisfactory outcome has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need for the most effective rotavirus vaccines. Therefore, the present scenario demands the development of a highly effective rotavirus vaccine. In this regard, inactivated rotavirus vaccine concept holds much promise for reducing the current disease burden. Recent advancements in developing an inactivated rotavirus vaccine indicate a significant progress towards disease prophylaxis and control.

Indexed as

AdolescentBangladeshChildChild, PreschoolHumansInfantInfant, NewbornRotavirusRotavirus InfectionsRotavirus VaccinesRotavirus VaccinesEnvironmental enteropathyGastroenteritisInactivated rotavirus vaccineLive attenuated vaccineRotarix™RotaTeq®Rotavirus

Identifiers

PMID29047020
OpenAlexW2765887889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.